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Background 
Colorectal cancer (CRC) incidence is increasing and evidence suggests that bowel microbiome mala-
daptation may be associated with colorectal carcinogenesis. Antibiotic consumption may cause bowel 
microbiome imbalance but research assessing an association between antibiotic exposure and CRC is 
inconsistent. The aim of this systematic review and meta-analysis was to appraise and synthesise the 
available evidence. 
Methods  
MEDLINE, EMBASE and CINAHL databases were searched for published observational studies. We in-
cluded eight studies of 3,408,312 patients. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) 
for the odds of CRC following antibiotic exposure were estimated. Sensitivity analyses were performed 
according to exposure definition, study design and risk of bias.  
Results 
A weak association between antibiotic exposure and CRC was demonstrated when exposure was as-
sessed cumulatively by the number of prescriptions (OR 1.204, 95% CI 1.097-1.322, p <0.001) or du-
ration of antibiotic exposure (OR 1.168, 95% CI 1.087-1.256, p <0.001).  Antibiotic exposure assessed 
as a binary variable demonstrated no association with CRC. 
Conclusion 
The findings suggest a weak association between cumulative antibiotic consumption and risk of CRC 
but no causal conclusions can be made. Limitations include the heterogeneity and quality of the avail-
able research, particularly with regard to measurement of antibiotic exposure. 
 
What does this paper add to the literature? 
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This systematic review synthesises and appraises the current evidence for a potential association be-
tween antibiotic exposure and CRC. Specifically, it highlights limitations in the available research that 
should be addressed in future research. 
 
1. Introduction 
The incidence of colorectal cancer (CRC) is increasing worldwide. In 2012, it was the third most com-
mon cancer globally and second most common in Europe (1). Recognized risk factors include family 
history, body mass index, smoking, diet, and inflammatory bowel disease (IBD) (2). Recent studies 
suggest that antibiotic exposure may also be a risk factor for CRC, increasing the risk of carcinogenesis 
through bowel microbiome imbalance (3-13).   The bowel microbiome is a diverse composition of 
approximately 100 trillion micro-organisms that play a role in digestion, the immune system and pro-
tection from pathogenic organisms (11, 14-16). Maladaptation of the bowel microbiome may relate 
to the development of CRC through several mechanisms, including chronic inflammation, altered ef-
fects on the local immune system or toxins and carcinogenic metabolites released by the bowel flora 
(11, 14, 15, 17).   
Antibiotic use can affect the bowel microbiome by reducing the diversity of the gut flora within a day 
of starting antibiotics and this may persist for a prolonged period (18-23).  This effect differs between 
individuals and depends on antibiotic class, route of administration and duration of use (18-21, 24).  A 
causal relationship between antibiotic consumption and CRC would be of considerable concern given 
the increasing rates of antibiotic use within Europe, especially within the elderly where CRC incidence 
is higher (22, 23, 25). However, current research investigating an association between antibiotic ex-
posure and colorectal carcinoma has been inconclusive and inconsistent (3-10). 
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A systematic review and meta-analysis of observational studies was performed to appraise and syn-
thesise published studies investigating the relationship between antibiotic exposure and incident col-
orectal adenoma and carcinoma. The aim was to assess whether the use of antibiotics is associated 
with the development of pre-cancerous or cancerous lesions in adults. 
 
2. Methods 
This was a systematic review and meta-analysis of observational studies. A protocol was prospectively 
registered with the International prospective register of systematic reviews (PROSPERO) database 
(https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=79979). The Meta-analysis Of 
Observational Studies in Epidemiology (MOOSE) guidelines were used for reporting(26).   
 
Search Strategy and Study Eligibility  
A comprehensive electronic literature search strategy was constructed using both medical subject 
heading (MeSH) terms and free text search terms relating to antibiotics and colorectal adenomas or 
carcinomas. The search strategy was created by three investigators (LS, NO and UN) and key words 
selected by two clinicians (LS and NO). The search was conducted by LS using Ovid, Wolters Kluwer 
online search tool.  Three electronic databases were searched: MEDLINE, EMBASE and CINAHL. The 
search strategy was produced initially in accordance with MEDLINE (see supplementary figure S1), 
then adapted to the other databases. There were no restrictions in terms of language or date. Hand 
searching of references of relevant studies was also undertaken. The initial search was undertaken on 
the 23rd October 2017 and repeated on the 25th June 2018.  
Inclusion criteria were published case-control or cohort studies from primary and secondary care that 
investigated the association between antibiotic exposure and incident colorectal adenoma or carci-
noma in adults over 18 years of age. Randomised control trials, case series and case reports were 
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excluded. The review protocol stated that studies enrolling patients less than 30 years old, patients 
with IBD or patients with a genetic predisposition to CRC were to be excluded. However it was subse-
quently decided to include these studies because these individuals only comprised a relatively small 
proportion of the included population. Sensitivity analyses were conducted to assess the impact these 
studies had on the overall risk estimates. Potentially eligible studies were extracted and organised in 
EndNote software, Thompson Reuters. Two investigators (LS and NO) independently reviewed the 
titles and abstracts. Eligible studies at this stage underwent a full text paper review against our inclu-
sion and exclusion criteria by three authors (LS, NO and HA).  
 
Data extraction 
For each eligible observational study, data extraction was performed by two reviewers independently 
(LS and NO). Data were collected on the primary author, date of publication, type of study, the country 
and setting of the study and duration of follow-up. Main study data extracted were patient de-
mographics, sample size, number of cases and controls in case-control studies and the number of 
exposed and unexposed participants in cohort studies, which antibiotic or antibiotics were assessed, 
and the primary outcome — incident colorectal adenomas or carcinomas. These data were collected 
for the meta-analysis but also to assist with sensitivity analyses. Data on subject inclusion and exclu-
sion criteria were recorded in order to assess for potential confounding and limiting factors. Extra 
information was requested from three authors for the meta-analysis, correspondence was received 
from one author initially and a second after the initial meta analysis was conducted.  
 
Risk of bias and study quality assessment 
Studies were assessed for methodological quality and risk of bias using the Effective Public Health 
Practice Project (EPHPP) quality assessment tool(27). EPHPP assesses quantitative studies based on a 
number of components resulting in either a weak, moderate or strong rating as well as an overall 
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global rating of study strength. This assessment was performed independently by two reviewers (LS 
and NO). Disagreements were discussed and resolved by a third reviewer (HA). 
 
Data analysis and synthesis 
Data were pooled statistically and meta-analyses conducted on available outcomes using a random-
effects model. All analyses were undertaken and forest plots created using Comprehensive Meta-
Analysis software (version 3). Results were expressed as Odds Ratios (OR) with 95% confidence inter-
vals (95% CI) for dichotomous outcomes. In some cases, relative risks (RR) were used in the meta-
analyses, as they are interchangeable and a good estimate of OR when the disease or outcome is rare 
in the population (typically prevalence less than 10%) as is the case in CRC or colorectal adenomas(28, 
29). 
Mean effect sizes (MES) were estimated for different types of antibiotic exposures from the same 
studies. This integrative approach is characterised by the inclusion of multiple effect sizes per study 
and is a novel approach in dealing with effect size multiplicity in systematic reviews and meta-analyses 
(30).  
Higher antibiotic exposure was categorised as more than 6 courses, reflecting definitions in 4 studies. 
Where antibiotic duration was expressed as days of use, we defined more than 2 months as higher 
use . The rationale for this was that most antibiotics are prescribed for respiratory tract infections with 
course durations of 6-10 days equating to about 60 days of use if 6 courses were prescribed as per the 
previous definition (31, 32).  
Sensitivity analyses were performed according to age, inclusion of patients with IBD or diabetes and 
risk of bias for the key review findings. These were undertaken as patients with CRC under the age of 
30 potentially may be more likely to have a genetic predisposition and those with diabetes or IBD are 
at an increased risk of CRC compared to the general population. We also did a post-hoc sensitivity 
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analysis excluding the study by Friedman et al (9).  The published study methods suggested that this 
study only included patients more than 20 years old. However, later contact with the author revealed 
the study did not restrict based on age and included patients <18 years. Therefore, sensitivity analyses 
were undertaken to assess its impact. 
Statistical tests for heterogeneity were performed and assessment undertaken for evidence of publi-
cation bias graphically using Funnel plots and statistically using Egger s test (33).  
For outcomes for which it was not possible to produce a meta-analysis, data was narratively synthe-
sized. No subgroup analyses were conducted. 
 
3. Results 
Study characteristics  
Eight studies were included in this systematic review. Three were cohort studies (4, 6, 7) and five were 
case-control studies (3, 5, 8-10), of which four were nested case-control studies (3, 5, 9, 10) (Figure 1). 
Detailed study characteristics and results are shown in table 1 and supplementary figure S2 respec-
tively. 
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PRISMA 2009 Flow Diagram(34) 
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Figure 1. PRISMA flow diagram of results of database literature searching. *Excluded references (35-38).  
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Refer-
ence 
Cou
ntry 
Population Interven-
tion 
Comparison Outcome Study 
Design 
Sam-
ple 
size 
Duration from 
antibiotic expo-
sure to CRC/ad-
enoma diagno-
sis 
Main indica-
tion for an-
tibiotic ex-
posure 
Boursi 
et al, 
2015 
I -
pact of 
antibi-
otic ex-
posure 
on the 
risk of 
colo-
rectal 
a er  
U.K. The Health Im-
provement Net-
work (THIN). In-
clusion criteria - 
aged >40 years. 
Exclusion crite-
ria - IBD, CRC 
syndromes and 
incomplete rec-
ords. 
Sex - 55.1% 
male in cases 
and controls 
Multiple 
Antibiotic 
classes * 
Four controls 
matched ac-
cording to age, 
sex, GP practice 
site and dura-
tion of follow 
up 
Colorectal 
cancer 
Nested 
Case 
control 
103,04
4 
not restricted 
in main study 
results (Median 
follow up 6.5 
years) 
Most com-
mon indica-
tion was res-
piratory 
tract infec-
tion 
Cao et 
al, 2017 
Lo g-
term 
use of 
antibi-
otics 
and risk 
of colo-
rectal 
ade-
o a  
U.S.
A. 
Nurses  Health 
Study (NHS) - 
Female nurses 
only.  Inclusion 
criteria – aged ≥ 
60 in 2004, re-
ported history 
of antibiotic ex-
posure and at 
least one colon-
oscopy be-
tween 2004-
2010. Exclusion 
criteria – 
UC/CRC or 
polyp before 
2004 
Antibiotics 
in general 
Control within 
same 2-year 
period as cases 
with a normal 
colonoscopy 
Colorectal 
adenoma 
Cohort 16,642 not restricted not stated 
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Dik et 
al, 2015 
Fre-
quent 
Use of 
Antibi-
otics Is 
Associ-
ated 
with 
Colo-
rectal 
Cancer 
Risk: 
Results 
of a 
Nested 
Case-
Control 
“tudy  
Net
her-
land
s 
Achmea Health 
Database. Inclu-
sion criteria – 
aged >18 years 
at CRC diagno-
sis between 
2006-11. Exclu-
sion criteria – 
IBD, < 6 years 
follow-up. 
Sex – 47.1% 
male in cases 
and controls 
Multiple 
Antibiotic 
classes ** 
Four controls 
matched ac-
cording to sex 
and date of 
birth 
Colorectal 
cancer 
Nested 
Case 
control 
20,017 1-6 years not stated 
Falagas 
et al, 
1998 
Late 
Inci-
dence 
of Can-
cer Af-
ter 
Metro-
nida-
zole 
Use: A 
Matche
d Met-
ronida-
zole 
User/N
onuser 
“tudy  
U.S.
A. 
Group Health 
Cooperative 
(GHC). Inclusion 
criteria – met-
ronidazole 
script issued be-
tween 1st Jan 
1975 – 31st De-
cember 1983 
for exposure 
group. Age >18 
years. Exclusion 
criteria not 
stated. 
Sex proportions 
not stated  
Metronida-
zole 
Controls 
matched for 
age, gender 
and year of en-
rolment in GHC 
Colorectal 
cancer 
Cohort 10,444 > 7 years not stated 
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Fried-
man et 
al, 1998 
Drugs 
and co-
lon can-
er  
U.S.
A. 
Kaiser Perma-
nente Medical 
care pro-
gramme, Utah 
residents and 
Minnesota. In-
clusion criteria 
–CRC aged 30-
79 between 1st 
Oct 1991 – 30th 
Sept 1994. Ex-
clusion criteria 
– not 
black/white or 
Hispanic ethnic-
ity, ot mental 
o pete t  to 
complete inter-
view, IBD or 
FAP. 
Sex proportions 
not stated 
Penicillin 
(and other 
drugs) 
Controls 
matched ac-
cording to sex 
and 5-year age 
group 
Colorectal 
cancer 
Case 
control 
4403 'about 2 years' not stated 
Fried-
man et 
al, 2009 
Epide-
mio-
logic 
evalua-
tion of 
phar-
maceu-
ticals 
with 
limited 
evi-
dence 
of car-
cino-
genic-
ity  
U.S.
A. 
Kaiser Perma-
nente Medical 
care pro-
gramme. Inclu-
sion criteria – 
CRC diagnosed 
between Aug 
1994 – June 
2006. Age not 
restricted.  Ex-
clusion criteria 
and age range 
not stated. 
Sex proportions 
not stated 
Metronida-
zole (and 
other 
drugs) 
Ten controls 
matched ac-
cording to sex, 
year of birth 
and year of 
starting drug 
Colon can-
cer 
Nested 
Case 
control 
113,27
8 A 
≥ 2 years not stated 
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Kil-
kkinen 
et al, 
2008 
A ti i-
otic use 
pre-
dicts an 
in-
creased 
risk of 
a er  
Fin-
land 
Finland Popula-
tion register, 
linkage with 
Finnish Cancer 
and Drug pre-
scription Regis-
tries. Inclusion 
criteria – aged 
30-79 and resi-
dent in Finland 
on 1st Jan 1995. 
Exclusion crite-
ria – diagnosed 
with CRC with 
1953 and 1997 
or died be-
tween 1st Jan 
1995 and 31st 
Dec 1997. 
Sex proportions 
not stated 
Antibiotics 
in general 
Not stated Colon and 
rectal can-
cer 
Cohort 3,112,6
24 
not restricted B1 not stated 
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Wang 
et al, 
2014 
I fe -
tion, 
antibi-
otic 
therapy 
and risk 
of colo-
rectal 
cancer: 
A na-
tion-
wide 
nested 
case-
control 
study in 
pa-
tients 
with 
Type 2 
diabe-
tes 
melli-
tus  
Tai-
wan 
Taiwan National 
Health Insur-
ance (NHI), Dia-
betic cohort. In-
clusion criteria 
– Type 2 Diabe-
tes between 1st 
Jan and 31st Dec 
2000. Exclusion 
criteria – aged 
<30 or >100 
years, died be-
fore 1st July 
2000, potential 
Type 1 Diabe-
tes, history of 
IBD or CRC, co-
lon diverticulo-
sis diagnosed 1 
year before 
CRC, <1year be-
tween antibiot-
ics and CRC di-
agnosis. 
Sex – colon can-
cer, 54.02% 
male in cases 
and controls; 
rectal cancer 
56.34% in cases 
and controls 
Antibiotics 
in general 
Up to four con-
trols, matched 
according to 
sex, age (within 
5 years) and 
follow up dura-
tion 
Colon and 
rectal can-
cer 
Nested 
Case 
control 
27,860 >  1 year C1 not stated 
 
 
 
 
 
 
 
Table 1. Detailed Study Characteristics  
* Antibiotic classes included Penicillin, Cephalosporins, Macrolides, Tetracyclines, Sulphonamides, Quinolones, Nitroimidazoles  
** Antibiotic classes included Penicillin, Macrolides, Tetracyclines, Sulphonamides and trimethoprim, Quinolones, Nitrofurantoin derivatives 
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AExact number of controls not stated - approximate value based on paper statement that 10 controls were matched to each case. 
 
B1Study states that limiting the result to those with at least 5 years follow did not significantly affect the results. 
 
C1Mean duration from exposure to CRC was 1,424 days for colon cancer and 1,397 days for rectal cancer 
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Risk of bias and quality assessment 
Six studies scored a moderate rating for quality and risk of bias according to the EPHPP. Two studies 
achieved a strong global rating (3, 8) (Table 2).  
 
Study Study De-
sign 
Selection 
bias Study design Confounders Blinding 
Data collec-
tion method 
Withdrawals and 
dropouts Global rating 
S M W S M W S M W S M W S M W S M W NA S M W 
Boursi, 2015 Nested 
Case-con-
trol  X   X   X   X  X      X X   
Cao, 2017 Cohort 
Study   X   X  X    X   X    X   X  
Dik, 2015 Nested 
Case-con-
trol 
 X   X    X  X   X     X  X  
Falagas, 1998 Cohort  
 X   X    X  X   X     X  X  
Friedman, 
1998 
Case-con-
trol  X   X  X    X   X     X X   
Friedman, 
2009 
Nested 
Case-con-
trol 
 X   X    X  X   X     X  X  
Kilkkinen, 
2008 
Cohort  
 X   X    X  X   X     X  X  
Wang, 2014 Nested 
Case-con-
trol 
 X   X    X  X   X  X     X  
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Table 2. Methodological quality and risk of bias assessment using the Effective Public Health Practice Project (EPHPP) tool.  
Key for study ratings, S – strong, M – moderate and W – weak, NA – not applicable.  
 
 
 
 
 
 
Antibiotic exposure and risk of adenoma or CRC 
Effect of any antibiotic exposure  
FIGURE 2 HERE 
 
Fig 2. Odds Ratios (OR) of developing CRC or adenomas with any antibiotic exposure. 
Forest plot of the odds of developing CRC with any antibiotic exposure. Study relative weighting: 
Cao 2018 - 21.32%, Dik 2016 - 22.64%, Falagas 1998 - 4.46%, Friedman 1998 - 13.80%, Friedman 
2009 - 17.27%, Wang 2014 - 20.50%. Key * mean effect size (MES). See supplementary figures S3-5 
for MES plots. 
 
 
Six studies reported associations between any antibiotic use and incident colorectal adenoma or car-
cinoma. Any antibiotic use was defined as any prescription for antibiotics during the study period. 
Meta-analysis of these studies showed that antibiotic exposure defined in this manner was not signif-
icantly associated with incident CRC (pooled odds ratio (OR) 1.058, 95% CI 0.913-1.225, p=0.453). Re-
stricting the analysis based on study participants age, study quality (moderate quality, low risk of bias), 
and exclusion of studies including participants with IBD or type 2 diabetes did not significantly affect 
our estimates. Removing the study by Friedman et al (9) resulted in an increase in the OR to 1.127 
(95% CI 0.992-1.280) but the association remained statistically non-significant (p=0.066). 
 
Effect of higher antibiotic exposure  
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FIGURE 3 HERE 
 
Fig 3. Odds Ratios (OR) of developing CRC or adenomas in patients with higher antibiotic exposure. 
Forest plot of the odds of developing CRC or adenomas with higher antibiotic exposure. Study rela-
tive weighting: Boursi 2015 - 35.47%, Cao 2018 - 13.45%, Dik 2016 - 23.44%, Kilkkinen 2008 - 
27.64%. Key - Boursi 2015 = > 10 course of antibiotics, Cao 2018 = > 2 months of antibiotics, Dik 
2016 = > 8 courses of antibiotics, Kilkkinen 2008 = > 6 course of antibiotics.  * mean effect size 
(MES). See supplementary figures S6-8 for MES plots. 
 
 
Four studies reported associations between stratified antibiotic exposure and incident CRC or adeno-
mas with comparable higher antibiotic exposures. Higher antibiotic exposure was defined as more 
than 6 courses during the study period (range — more than 6 to more than 10 courses). More than 2 
months duration of antibiotics was included within this analysis as it was comparable to the course 
ranges described above. Meta-analysis found that high antibiotic exposure, as described above, was 
associated with an increased odds of CRC (pooled OR 1.204, 95% CI 1.097-1.322, p=0.000).  Restricting 
the analysis, as described with the previous outcome, did not affect our estimates. 
 
More Prolonged duration of antibiotic exposure 
 
FIGURE 4 HERE 
 
Fig 4. Odds Ratios (OR) of developing CRC or adenomas in patients with more prolonged antibiotic exposure.  
Forest plot of the odds of developing CRC with more prolonged antibiotic exposure. Study relative 
weighting: Boursi 2015 - 74.82%, Cao 2018 - 1.42%, Dik 2016 - 23.76%. Key - Boursi 2015 = > 56 days 
duration, Cao 2018 = > 2 months of antibiotics, Dik 2016 = > 70 days duration.  * Mean effect size 
(MES). See supplementary figure S9 for MES plots. 
 
 
Three studies reported cumulative duration of antibiotic exposure and incident colorectal adenoma 
or cancer, with comparable more prolonged duration categories. These studies assessed cumulative 
exposure as opposed to courses of potentially variable duration. More prolonged duration was ana-
lysed (range — more than 56 days to more than 70 days of antibiotic exposure). Meta-analysis of these 
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studies demonstrated that more prolonged antibiotic exposure was associated with an almost 17% 
increased odds of CRC (pooled OR 1.168, 95% CI 1.087-1.256, p=0.000). Again restricting the analysis 
did not affect our estimates.   
 
Risk of Bias across studies 
The funnel plot suggests there is potentially publication bias based on asymmetry (see supplementary 
figure S10). However the Eggers regression intercept (Intercept =-1.471, p=0.520) suggests no publi-
cation bias. This must be interpreted with caution however as its use with less than 10 studies leads 
to a reduction in its power(39). 
 
GRADE Evaluation of Certainty of Findings 
'Summary of findings tables' were created for primary outcomes (see tables 3-5). Quality of evidence 
was assessed for each outcome using the five GRADE criteria (GRADEpro GDT) (39, 40). Decisions 
and justifications to down — or upgrade the quality of studies are documented within footnotes.  
Based on the GRADE certainty of evidence assessment, for the three exposures studied, the subse-
quent risk of developing CRC and adenomas has a very low certainty of evidence. 
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Question: Does any antibiotic exposure increase the risk of developing colorectal cancer and adenomas?  
Setting: Inpatient and outpatient  
Bibliography: Cao et al, Dik et al, Falagas et al, Friedman et al 1998, Friedman et al 2009 and Wang et al  
 
Certainty assessment № of patients 
№ of 
studies Study design Risk of bias Inconsistency Indirectness Imprecision Other considerations 
Antibiotic expo-
sure 
No Antibiotic ex-
posure 
Development of Colorectal Cancer or Adenomas 
6  observational 
studies  
serious a very serious b not serious  serious c publication bias strongly sus-
pected d 
Unable to calculate 
due to missing raw 
data 
Unable to calculate 
due to missing raw 
data 
(0.9
 
 
 
 
 
 
 
CI: Confidence interval; OR: Odds ratio 
Explanations 
a. One of the studies (Friedman et al 1998) had a low risk of bias, whereas the remaining five were high risk of bias due confounding factors and withdrawals and follow up. 
Please see Study Quality assessment for further details of risk of bias for each study.  
b. Downgraded on inconsistency due to a high I2 value of 79% and a large Chi Squared value.  
c. Downgraded due to wide confidence intervals, despite large sample size.  
d. Funnel plot shows asymmetry suggestive of publication bias.  
 
 
Question: Does higher antibiotic exposure increase the risk of developing colorectal cancer or adenomas?  
Setting: Inpatient and Outpatient  
Bibliography: Boursi et al, Cao et al, Dik et al and Kilkkinen et al  
 
Certainty assessment № of patients 
№ of 
studies Study design Risk of bias Inconsistency Indirectness Imprecision Other considerations 
High antibiotic ex-
posure 
No antibiotic ex-
posure 
Rela
(95%
Colorectal cancer or adenoma 
4  observational 
studies  
serious a serious b not serious  not serious  publication bias strongly sus-
pected c 
Unable to calculate 
due to missing raw 
data 
Unable to calculate 
due to missing raw 
data 
OR 1
(1.087 to
 
 
 
 
 
 
 
CI: Confidence interval; OR: Odds ratio 
Explanations 
a. Downgraded because apart from Boursi et al, the other studies had high risk of bias due to confounding factors.  
b. Downgraded due to a relatively elevated I2 of 62% and high Chi Squared value.  
c. Unable to formally assess publication bias as too few studies but strongly suspected based on fact it was strongly suspected in the above assessment (see table 3)  
 
Table 3. GRADE Assessment of whether antibiotic exposure increases the risk of developing CRC or adenomas. Please note that the risk of bias
Table 4. GRADE Assessment of whether higher antibiotic exposure increases the risk of developing CRC or adenomas. Please note that the risk of bias was assessed
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Question: Does more prolonged antibiotic exposure increase the risk of developing colorectal cancer or adenomas?  
Setting: Inpatient and outpatient  
Bibliography: Boursi et al, Cao et al and Dik et al.  
 
Certainty assessment № of patients 
№ of 
studies Study design Risk of bias Inconsistency Indirectness Imprecision Other considerations 
Prolonged Antibi-
otic Exposure 
No Antibiotic Ex-
posure 
Development of Colorectal cancer or adenoma 
3  observational 
studies  
serious a not serious  not serious  not serious  publication bias strongly sus-
pected b 
Unable to calculate 
due to missing raw 
data 
Unable to calculate 
due to missing raw 
data 
(1.0
 
 
 
 
 
 
 
 
 
CI: Confidence interval; OR: Odds ratio 
Explanations 
a. Downgraded as Cao et al is at high risk of bias due to withdrawal and drop-out rates whereas Dik et al is at high risk of bias due to confounding factor bias.  
b. Unable to formally assess publication bias as too few studies but strongly suspected based on fact it was strongly suspected in the above assessment (see table 3) 
 
 
Table 5. GRADE Assessment of whether more prolonged antibiotic exposure increases the risk of developing CRC or adenomas. Please note that
EPHPP 
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4. Discussion 
Summary of findings 
This systematic review found that antibiotic exposure, assessed as a binary variable, had no significant 
association with colorectal adenoma or carcinoma. However, when antibiotic exposure was catego-
rised using cumulative measures, such as individuals exposed to more than 6 courses of antibiotics or 
more than 2 months duration of treatment, they had a relatively small increased odds of developing 
colorectal adenoma or carcinoma. However, the observed association should be interpreted with cau-
tion due to the small effect size and potential for bias and confounding. 
Of the studies included in this systematic review, four found an association between antibiotic expo-
sure and CRC (3-6). Studies by Boursi et al and Dik et al categorised antibiotics according to class and 
demonstrated a dose dependent increase in CRC risk with penicillin whereas no linear relationship 
was demonstrated in Cao et al and Kilkkinen et al where antibiotics were not categorised according to 
class (3-6). The four remaining studies gave opposing results. Three studies focussed on specific anti-
biotic groups (penicillin and metronidazole). No association was found in two of these studies and the 
study by Friedman 09 et al showed reduced odds of developing CRC with metronidazole (7-9). Finally, 
Wang et al analysed the effect of general antibiotic exposure on CRC risk in a diabetic cohort and again 
found no association. However, further analysis demonstrated that anaerobic antibiotic exposure was 
associated with an increased CRC risk (10).  
Association does not necessarily imply causation and the Bradford-Hill criteria provides a useful frame-
work for appraising an association for possible causation (40). Firstly, current knowledge suggests that 
a potential association between antibiotic exposure and CRC is biologically plausible. It is known that 
the microbiome differs between individuals with CRC and healthy  people but also differs within the 
same individual between cancer tissue and unaffected bowel (18, 41-44). There is also experimental 
evidence from animal studies where mice without an established microbiome (germ-free) living in a 
germ free environment develop less CRC (14, 45, 46). It has been hypothesized that gut microbiome 
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imbalance could result in CRC formation by creating a pro-inflammatory environment via a number of 
mechanisms (47-50). Research has also resulted in different microbe populations being isolated lead-
ing to two proposed models, the a terial driver-passenger odel  and the alpha ugs  model (51, 
52).  Antibiotics are well known to alter the gut microbiome and it is via this mechanism it is speculated 
they might contribute to CRC development (18-21, 53). 
However, in spite of the above, the evidence against a causal relationship remains substantial. Uncer-
tainty about the temporality of an association is significant as it is not clear whether dysbiosis precedes 
CRC development or occurs as a result. In addition, there is experimental evidence supporting a link 
between microbiome dysbiosis and CRC but not with regard to antibiotics and CRC. Also the results of 
the included studies are mixed and do not consistently demonstrate an association. Finally, this review 
amalgamated all the observational research in this area and only demonstrates a weak association. 
This could be explained by bias within the studies, discussed below, but also by confounding factors,. 
One of which could include reduced immune system function resulting in an increased risk of cancer 
and infection necessitating antibiotic use. Another plausible confounder relates to health seeking be-
haviour, where those more likely to seek antibiotics maybe more likely to present with symptoms 
relating to CRC or attend screening.  
 
Strengths and limitations 
To the best of our knowledge, this is the first systematic review and meta-analysis of observational 
studies that quantify the association between antibiotic exposure and risk of CRC. All included studies 
were of at least moderate quality according to the EPHPP. Furthermore, the included studies had ad-
equate statistical power, with the meta-analysis sample sizes ranging from nearly 140,000 patients to 
more than 3 million.  
However, this review also has a number of significant limitations. Firstly, included studies were heter-
ogeneous in how antibiotic exposure was characterized from general exposure to focusing on specific 
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groups. The route and setting of antibiotic exposure differed between studies, with some focusing on 
an outpatient population whereas others included hospital inpatients and potentially intravenous ad-
ministration. These differences may impact the concentrations of antibiotic exposure but also classes 
of antibiotics used, leading to differing effects upon the individuals gut flora. A further area of heter-
ogeneity was with regard to how antibiotic exposure was stratified which led to some studies not 
being included in the quantitative synthesis. It is also important to note that the method of capturing 
data on antibiotic exposure differed between studies, from interviews and questionnaires to interro-
gation of healthcare databases.  
A number of studies did not stratify or consider all known confounding risk factors for CRC, thus po-
tentially confounding the study results. Of those studies that did include patients with IBD or poten-
tially familial CRC syndromes, the proportions were not stated. A further major limiting factor is the 
relatively short time between antibiotic exposure and the development of CRC in the majority of stud-
ies (table 1). It is generally hypothesised that colorectal carcinogenesis is a stepwise process that takes 
8-15 years to develop (3, 10), therefore follow up needs to be long enough to identify any causative 
links. In addition, antibiotic prescribing tends to be highest in children and the elderly within primary 
care (23). It is not clear if any included studies analysed antibiotic exposure during childhood, a poten-
tially crucial time period of dysbiosis.  Also, none of the included studies tried to differentiate micro-
biome associated events between initiation of CRC as polyp prevalence and progression through more 
advanced stages.  
Epidemiological approaches to bacterial driven mechanisms of CRC are limited by differences in com-
position and comparability between mucosal and stool samples, right and left colon, adenomas and 
carcinomas and the different molecular subtypes and clinical categories within CRC (54-56). This 
makes causality assessment for bacterial populations challenging. Available evidence of adaptation 
and evolution in the commensal microbiome also suggests that comparability between studies is chal-
lenging and makes a further likely contribution to heterogeneity (57). Another potential limitation is 
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the inclusion of adenomas within our analysis as it has been suggested the microbiome may differ 
along the adenoma-colorectal cancer continuum (56). However, currently there is a paucity of good 
quality evidence  to support changes in the microbiome at different stages leading up to CRC.  
Only one study analysed patients according to lesion characteristics (Cao et al) and whether partici-
pants were symptomatic therefore limiting further analyses. This study demonstrated longer antibi-
otic exposure at age 40-59 was more strongly associated with proximal adenomatous lesions (4). They 
also demonstrated that between 15-25% of participants had symptoms at the time of endoscopy (4).  
Finally, the indication for antibiotics was only analysed in one study (Cao et al). This raises the concern 
that antibiotics could have been given for gastrointestinal infection, which is acting as a confounding 
factor. Another plausible explanation is that patients presenting with symptoms suggestive of 
gastrointestinal infection had already developed CRC. 
 
Conclusions 
Our findings suggest there may be an association between antibiotic consumption and the risk of in-
cident CRC. However, published literature is heterogeneous and inconsistent with a number of poten-
tially significant confounding factors and therefore no causal conclusions can be made. Further large 
cohort studies with clearly defined antibiotic exposure, adjustment for confounding factors and long-
term follow-up are needed to allow more conclusive understanding of whether there is a causal rela-
tionship.   
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